ABSTRACT Objective Radium-223(223Ra) is indicated for patients (p) with metastatic castration resistant prostate cancer (mCRCP). Objectives The aim of this study was to evaluate the role of baseline c
Distribution of class labels and subtypes for the 892 samples with a proper class label. and denote the number of negative (good prognosis) and positive (poor prognosis) cases of for each subtype ,
